Real-world evidence of Trastuzumab Deruxtecan (T-DXd) Efficacy in HER2-expressing gynecological malignancies

Angeliki Andrikopoulou, Flora Zagouri, Kallirroi Goula, Dimitrios Haidopoulos, Nikolaos Thomakos, Anna Svarna, Meletios-Athanasios Dimopoulos, Michalis Liontos · 2024

Read Real-world evidence of Trastuzumab Deruxtecan (T-DXd) Efficacy in HER2-expressing gynecological malignancies by Angeliki Andrikopoulou, Flora Zagouri, Kallirroi Goula, Dimitrios Haidopoulos, Nikolaos Thomakos, Anna Svarna, Meletios-Athanasios Dimopoulos, Michalis Liontos (2024) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-11622448.txt.

Description

A drug that couples an antibody to a cell-killing payload, called T-DXd, has shown strong results against cancers that display the HER2 protein. Eight clinicians in Athens report in 2024 how it worked in their own clinic for gynecological cancers. They review ten patients with advanced uterine, ovarian, or cervical disease. All had already passed through several earlier treatments, a median of four lines. The drug was given by infusion every three weeks.

Half the patients saw their tumors shrink, including two who had received an earlier HER2 drug. One more held stable at twelve weeks. The middle time before the disease advanced again was 5.4 months. The authors present the series as real-world support for the drug in these cancers.

Catalog record

CREATORAngeliki Andrikopoulou, Flora Zagouri, Kallirroi Goula, Dimitrios Haidopoulos, Nikolaos Thomakos, Anna Svarna, Meletios-Athanasios Dimopoulos, Michalis Liontos
YEAR2024
COLLECTIONPAPERS
FORMATTXT
FILE SIZE25 KB
VERSION1.0
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC11622448

Browse the full library · About the Tower of Babel